Advertisement Pharmaceutical Business review - Page 4736 of 5290 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 18, 2026

Roche agrees $1bn deal with Dualitas for bispecific antibody research

Roche and Dualitas Therapeutics have entered a research collaboration and licence agreement that could reach a potential value of up to $1bn, aiming to discover and develop bispecific antibodies for immunology and inflammation (I&I) diseases.

The collaboration will leverage Dualitas’ proximity biology capabilities to produce bispecific antibody therapeutics. Credit: THICHA SATAPITANON / Shutterstock.com.